Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.
0
investigations
0
debates
auto_detected
source
Scores
Composite
0.700
Importance
0.900
Tractability
0.750
Novelty
0.700
Priority
0.910
Market Price
0.500